Bästa Lancet Oncology podcaster (2024)

1
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma 15:07

26d ago15:07

15:07

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Read the full Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(…

1
In conversation with... Steven Horwitz 15:07

27d ago15:07

15:07

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.Av The Lancet

1
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination 17:21

2M ago17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanon…

1
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics 40:45

2M ago40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Read the Commission: https:/…

1
In conversation with... May Abdel-Wahab and Andrew Scott 40:45

2M ago40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.…

1
In conversation with... Zachary Zumsteg 17:21

2M ago17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.Av The Lancet

1
In conversation with... Kanwal Raghav 13:22

3M ago13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.…

1
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) 13:22

3M ago13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’. Read the full article: https://ww…

1
In conversation with... Emmy Boerrigter 11:41

4M ago11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.Av The Lancet

1
Emmy Boerrigter on dose selection of novel anticancer drugs 11:41

4M ago11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lan…

1
In conversation with... Hisham Mehanna and Sue Yom 36:56

5M ago36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.Av The Lancet

1
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations 36:56

5M ago36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints. Tell us what you thought about this episode Continue this conversation on social! F…

1
In conversation with... Garth Strohbehn and Katie Lichter 24:08

6M ago24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.Av The Lancet

1
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment 24:08

6M ago24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversatio…

1
In conversation with... James Shultz, Ana Patricia Ortiz, and Leticia Nogueira 35:05

7M ago35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…

1
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean 35:05

7M ago35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…

1
In conversation with... Bernardo Goulart 11:22

8M ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Av The Lancet

1
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials 11:22

8M ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_…

1
In conversation with... Maria Kyrgiou 25:42

9M ago25:42

25:42

In a special episode on International Women's Day 2024, we speak with Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.Av The Lancet

1
Maria Kyrgiou on innovations in gynaecological cancers and global disparities 25:42

9M ago25:42

25:42

In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twi…

1
In conversation with... Georgios Lyratzopoulos 34:43

9M ago34:43

34:43

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.Av The Lancet

1
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers 34:43

9M ago34:43

34:43

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia. Tell us what you thought about this episode Continue this conversation on social! Follow us tod…

1
In conversation with... Mike Sathekge 16:06

10M ago16:06

16:06

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’Av The Lancet

1
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer 16:06

10M ago16:06

16:06

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’ Read the full article: https://www.thelancet.com/journals/lanonc/article/…

1
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma 13:53

11M ago13:53

13:53

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma. Tell us what you thought about this episode Continue this con…

1
In conversation with... Shankar Siva 13:53

11M ago13:53

13:53

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.Av The Lancet

1
Neerja Bhatla on a new quadrivalent HPV vaccine 12:24

12M ago12:24

12:24

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India. Read the full article: https://www.thelancet.com/journals/la…

1
In conversation with... Neerja Bhatla 12:24

12M ago12:24

12:24

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.Av The Lancet

1
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery 43:49

1y ago43:49

43:49

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https:…

1
In conversation with... Chandra Are 43:49

1y ago43:49

43:49

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.Av The Lancet

1
In conversation with... Philipp Karschnia 17:10

1y ago17:10

17:10

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.Av The Lancet

1
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma 17:10

1y ago17:10

17:10

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma. Read the full Policy Review: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2…

1
In conversation with... Wanda Cui

1y ago

—

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Av The Lancet

1
Wanda Cui on measuring ovarian toxicity 10:37

1y ago10:37

10:37

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought abo…

1
Ticiana Leal on Tumour Treating Fields 9:01

1y ago9:01

9:01

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on …

1
In conversation with... Ticiana Leal 9:01

1y ago9:01

9:01

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.Av The Lancet

1
In conversation with... Xuesong Han 12:31

1+ y ago12:31

12:31

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.Av The Lancet

1
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA 12:31

1+ y ago12:31

12:31

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us wh…

1
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma 33:50

1+ y ago33:50

33:50

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid…

1
In conversation with... Carlos Fernández de Larrea and Damian Green 33:50

1+ y ago33:50

33:50

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.Av The Lancet

1
In conversation with... Madeline Pe 14:01

1+ y ago14:01

14:01

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.Av The Lancet

1
Madeline Pe on the SISAQOL initiative 14:01

1+ y ago14:01

14:01

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative. Read the full article: https://www.thelancet.com/journals/lanonc/article/P…

1
In conversation with... Kadia Petricca and Joyce Kambugu 28:40

1+ y ago28:40

28:40

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.…

1
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children 28:40

1+ y ago28:40

28:40

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”. Read the full…

1
In Conversation With... Mark Lythgoe 14:11

1+ y ago14:11

14:11

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".Av The Lancet

1
Mark Lythgoe on UK oncology drug approval after Brexit 14:11

1+ y ago14:11

14:11

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit". Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/th…

1
In conversation with... Janet Brown 20:43

1+ y ago20:43

20:43

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.Av The Lancet

1
Janet Brown on the phase 2/3 STAR trial 20:43

1+ y ago20:43

20:43

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma. Read the full article: Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cel…

1
Valerie Speirs on biomarkers in male breast cancer 17:40

2y ago17:40

17:40

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer. Read the full article: Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cance…

1
In conversation with... Valerie Speirs 17:40

2y ago17:40

17:40

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.Av The Lancet

Podcaster värda att lyssna på

Lancet Oncology podcaster

Podcaster värda att lyssna på

Snabbguide